Day Two

• Outlining the first example of a Korean CNS asset out-licensed at Phase III vs.typical earlier-stage licensing deals
• Demonstrating how Korean biopharma can retain and elevate their clinical assets to maximize financial returns
• Innovative collaboration models in the biopharma industry between Korea and China

• Which CNS indications and targets hold the greatest promise for investable disease‑modifying therapies?
• What stage and type of data are needed to confidently support safety, target engagement, and MoA of new targets under evaluation?
• Do you prioritize new modalities aligned with in‑house expertise, or are you open to partnering with specialists in novel modalities?

Structured networking session offering the chance to connect directly with pharma panellists, ask targeted questions, and continue the discussion.

• Highlighting how long-acting microsphere technology could be applied for CNS indications, with reference to G2GBIO’s pipeline as an example
• Explaining the drug-release mechanism of microspheres in the CNS
• Demonstrating PK profile of monthly injectable Donepezil in animals and humans

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share

opinions around pre-assigned topic areas:

• What can we learn and actionably take away from Denali’s enzyme transport therapy approval?
• Comparing dual shuttle strategies vs combining a shuttle with a neuronal cell-specific target: what are the most promising approaches in development?
• How can we better understand the receptor distribution, transcytosis mechanisms and biology of new potential BBB targets?

• Exploring Lundbeck’s evolution and outlook within neuroscience
• Lundbeck R&D tactics for pipeline derisking through rigorous development process
• Spotlighting on Lundbeck’s pipeline innovation and importance of collaborations and partnerships to advance neuroscience

• Reviewing AbbVie’s abundant pipeline spanning a range of assets in mood disorders
• Highlighting AbbVie’s priorities and commitment to advancing treatments in MDD, BPD and Schizophrenia
• General overview of programs in Neurology, Neurodegeneration, Migraine and Pain

• Reviewing pipeline development history of innovative botanical drug candidate, MT101, for Parkinson’s Disease
• Demonstrating how Nurr1 activation induces dopaminergic gene expression and proteasome activation, subsequently inhibiting alpha-synuclein aggregation
• Showcasing Phase I safety and tolerability data in elderly populations and detailing future directions for Phase IIa initiation in US

• Pathological Mechanism: β2m accumulation disrupts the neuro-immune axis and co-aggregates with Aβ, accelerating neurotoxic pathways and cognitive decline independently of amyloid plaques
• Selective Strategy: ADEL-Y03 utilizes an epitope-focused design to specifically neutralize “free” β2m while sparing MHC-I, ensuring high safety and selectivity
• Therapeutic Efficacy: Preclinical data confirms ADEL-Y03 rescues cognitive deficits in AD models and shows potential broader indications, including systemic fibrosis

• Case study 1: Leveraging protein factors found specifically in amniotic fluid todetect autism prior to third trimester
• Case study 2: Utilizing CRISPR technology to identify markers present before the onset of glioblastoma

• Novel Target Discovery and AI Platform: Unlocking deeper therapeutic insights through the AI-driven discovery of neuroregenerative targets (encompassing neurogenesis, neuroprotection, and synaptogenesis) and the identification of mechanistically driven biomarkers
• First-in-Human Translation in ALS: Translating insights from a First-in-Human (FIH) study evaluating a novel neuroregenerative therapeutic for Amyotrophic Lateral Sclerosis (ALS), while rethinking the clinical utility and limitations of peripheral blood Neurofilament Light (NfL) chain as a general structural marker
• MoA-Specific Biomarkers in Companion Canine Patients: Showcasing the robust translational value of proprietary, mechanism-specific biomarker(s), which directly correlate with disease severity across diverse real-world companion canine patients suffering from natural neurodegenerative diseases
• Strategic Imperatives: Defining actionable clinical development and biomarker strategies to bridge the translational gap, successfully delivering genuine, disease-modifying therapies to patients